In cancer cells missing the MTAP gene, a buildup of MTA naturally blocks PRMT5, a key enzyme for gene regulation; blocking MAT2A with IDE397 worsens this block by lowering SAM, further impairing gene control mechanisms.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PRMT5 inhibition correlates with clinical response to MAT2A inhibitors across MTAP-deleted tumor types in multiple trials.
A systematic review and meta-analysis of all published clinical trials using MAT2A inhibitors in MTAP-deleted cancers, correlating pre-treatment PRMT5 activity (via methylation signatures) and post-treatment changes in RNA splicing profiles with objective response rates and survival outcomes.
Whether enhancing PRMT5 inhibition via MAT2A blockade improves survival compared to PRMT5 inhibitors alone in MTAP-deleted tumors.
A double-blind RCT of 250 patients with MTAP-deleted solid tumors randomized to IDE397 + PRMT5 inhibitor vs. PRMT5 inhibitor alone vs. placebo, measuring tumor response, PRMT5 methylation targets (e.g., histone H4R3me2s), and RNA splicing changes as biomarkers over 18 months.
Whether baseline PRMT5 activity predicts sensitivity to MAT2A inhibition in MTAP-deleted tumors.
A prospective cohort of 200 patients with MTAP-deleted tumors treated with IDE397, with pre-treatment tumor biopsies analyzed for PRMT5 expression, SAM levels, and methylation of known PRMT5 substrates, correlated with time to progression and response duration.
Whether tumors with higher MTA accumulation show greater PRMT5 suppression and better response to MAT2A inhibitors.
A matched case-control study comparing 50 responders to IDE397 with 50 non-responders, matched for tumor type and MTAP status, measuring pre-treatment MTA concentration, PRMT5 activity, and SAM levels in tumor tissue.
The relationship between MTA concentration and PRMT5 methylation activity in MTAP-deleted tumors across a broad patient population.
A cross-sectional analysis of 300 archived MTAP-deleted tumor samples measuring MTA levels via LC-MS and PRMT5 substrate methylation via immunohistochemistry, correlating these with tumor grade and histology.